Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin

F. A. Shepherd, L. Rotstein, M. E. Blackstein, R. Burkes, C. Erlichman, N. Iscoe, G. Kutas, K. Paul, P. Mah

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A group of 23 patients (20 male, 3 female) with hepatocellular carcinoma were treated by hepatic arterial infusion of 4'-epirubicin every 4 weeks. At each treatment, a catheter was inserted percutaneously into the main hepatic artery via the femoral artery under image intensification. Treatment consisted of a 24-h continuous HAI of epirubicin, 30 mg/m2/day for 3 days, without heparin. Eleven patients had only one infusion, 4 patients two infusions, 2 patients three infusions, 2 patients four infusions, and 1 patient six and eight infusions each. A partial response was seen in 3 patients, median duration 16 weeks (range 12-46 weeks). Seven patients remained stable, median duration 13 weeks (range 4-38 weeks). The median survival of the overall group was 18 weeks. Survival of responding, stable, and non-responding patients were 38 weeks, 19 weeks, and 10 weeks, respectively. Complications of catheter placement included asymptomatic dissection of the hepatic artery (3 patients), and asymptomatic thrombosis of the hepatic artery (3 patients). Eight patients experienced moderate nausea and vomiting, and 11 patients had moderate to severe alopecia. The granulocyte nadir was above 1000 μl in 83% of evaluable courses, 500-1000 μl in 6%, and less than 500 μl in 11% of courses. Two patients developed neutropenia-associated fever. A platelet nadir below 100,000/μl was seen after only 8% of courses, and only 1 patient had platelets below 50,000/μl. In conclusion, epirubicin has modest activity in hepatocellular carcinoma and is well tolerated when given by hepatic arterial infusion.

Original languageEnglish (US)
Pages (from-to)197-201
Number of pages5
JournalRegional Cancer Treatment
Volume3
Issue number4
StatePublished - 1990
Externally publishedYes

Fingerprint

Epirubicin
Hepatocellular Carcinoma
Liver
Therapeutics
Hepatic Artery
Blood Platelets
Catheters
Survival
Alopecia
Femoral Artery
Neutropenia
Granulocytes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology

Cite this

Shepherd, F. A., Rotstein, L., Blackstein, M. E., Burkes, R., Erlichman, C., Iscoe, N., ... Mah, P. (1990). Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin. Regional Cancer Treatment, 3(4), 197-201.

Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin. / Shepherd, F. A.; Rotstein, L.; Blackstein, M. E.; Burkes, R.; Erlichman, C.; Iscoe, N.; Kutas, G.; Paul, K.; Mah, P.

In: Regional Cancer Treatment, Vol. 3, No. 4, 1990, p. 197-201.

Research output: Contribution to journalArticle

Shepherd, FA, Rotstein, L, Blackstein, ME, Burkes, R, Erlichman, C, Iscoe, N, Kutas, G, Paul, K & Mah, P 1990, 'Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin', Regional Cancer Treatment, vol. 3, no. 4, pp. 197-201.
Shepherd FA, Rotstein L, Blackstein ME, Burkes R, Erlichman C, Iscoe N et al. Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin. Regional Cancer Treatment. 1990;3(4):197-201.
Shepherd, F. A. ; Rotstein, L. ; Blackstein, M. E. ; Burkes, R. ; Erlichman, C. ; Iscoe, N. ; Kutas, G. ; Paul, K. ; Mah, P. / Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin. In: Regional Cancer Treatment. 1990 ; Vol. 3, No. 4. pp. 197-201.
@article{c225feeea9364a6592c126c3af0417eb,
title = "Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin",
abstract = "A group of 23 patients (20 male, 3 female) with hepatocellular carcinoma were treated by hepatic arterial infusion of 4'-epirubicin every 4 weeks. At each treatment, a catheter was inserted percutaneously into the main hepatic artery via the femoral artery under image intensification. Treatment consisted of a 24-h continuous HAI of epirubicin, 30 mg/m2/day for 3 days, without heparin. Eleven patients had only one infusion, 4 patients two infusions, 2 patients three infusions, 2 patients four infusions, and 1 patient six and eight infusions each. A partial response was seen in 3 patients, median duration 16 weeks (range 12-46 weeks). Seven patients remained stable, median duration 13 weeks (range 4-38 weeks). The median survival of the overall group was 18 weeks. Survival of responding, stable, and non-responding patients were 38 weeks, 19 weeks, and 10 weeks, respectively. Complications of catheter placement included asymptomatic dissection of the hepatic artery (3 patients), and asymptomatic thrombosis of the hepatic artery (3 patients). Eight patients experienced moderate nausea and vomiting, and 11 patients had moderate to severe alopecia. The granulocyte nadir was above 1000 μl in 83{\%} of evaluable courses, 500-1000 μl in 6{\%}, and less than 500 μl in 11{\%} of courses. Two patients developed neutropenia-associated fever. A platelet nadir below 100,000/μl was seen after only 8{\%} of courses, and only 1 patient had platelets below 50,000/μl. In conclusion, epirubicin has modest activity in hepatocellular carcinoma and is well tolerated when given by hepatic arterial infusion.",
author = "Shepherd, {F. A.} and L. Rotstein and Blackstein, {M. E.} and R. Burkes and C. Erlichman and N. Iscoe and G. Kutas and K. Paul and P. Mah",
year = "1990",
language = "English (US)",
volume = "3",
pages = "197--201",
journal = "Regional Cancer Treatment",
issn = "0935-0411",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin

AU - Shepherd, F. A.

AU - Rotstein, L.

AU - Blackstein, M. E.

AU - Burkes, R.

AU - Erlichman, C.

AU - Iscoe, N.

AU - Kutas, G.

AU - Paul, K.

AU - Mah, P.

PY - 1990

Y1 - 1990

N2 - A group of 23 patients (20 male, 3 female) with hepatocellular carcinoma were treated by hepatic arterial infusion of 4'-epirubicin every 4 weeks. At each treatment, a catheter was inserted percutaneously into the main hepatic artery via the femoral artery under image intensification. Treatment consisted of a 24-h continuous HAI of epirubicin, 30 mg/m2/day for 3 days, without heparin. Eleven patients had only one infusion, 4 patients two infusions, 2 patients three infusions, 2 patients four infusions, and 1 patient six and eight infusions each. A partial response was seen in 3 patients, median duration 16 weeks (range 12-46 weeks). Seven patients remained stable, median duration 13 weeks (range 4-38 weeks). The median survival of the overall group was 18 weeks. Survival of responding, stable, and non-responding patients were 38 weeks, 19 weeks, and 10 weeks, respectively. Complications of catheter placement included asymptomatic dissection of the hepatic artery (3 patients), and asymptomatic thrombosis of the hepatic artery (3 patients). Eight patients experienced moderate nausea and vomiting, and 11 patients had moderate to severe alopecia. The granulocyte nadir was above 1000 μl in 83% of evaluable courses, 500-1000 μl in 6%, and less than 500 μl in 11% of courses. Two patients developed neutropenia-associated fever. A platelet nadir below 100,000/μl was seen after only 8% of courses, and only 1 patient had platelets below 50,000/μl. In conclusion, epirubicin has modest activity in hepatocellular carcinoma and is well tolerated when given by hepatic arterial infusion.

AB - A group of 23 patients (20 male, 3 female) with hepatocellular carcinoma were treated by hepatic arterial infusion of 4'-epirubicin every 4 weeks. At each treatment, a catheter was inserted percutaneously into the main hepatic artery via the femoral artery under image intensification. Treatment consisted of a 24-h continuous HAI of epirubicin, 30 mg/m2/day for 3 days, without heparin. Eleven patients had only one infusion, 4 patients two infusions, 2 patients three infusions, 2 patients four infusions, and 1 patient six and eight infusions each. A partial response was seen in 3 patients, median duration 16 weeks (range 12-46 weeks). Seven patients remained stable, median duration 13 weeks (range 4-38 weeks). The median survival of the overall group was 18 weeks. Survival of responding, stable, and non-responding patients were 38 weeks, 19 weeks, and 10 weeks, respectively. Complications of catheter placement included asymptomatic dissection of the hepatic artery (3 patients), and asymptomatic thrombosis of the hepatic artery (3 patients). Eight patients experienced moderate nausea and vomiting, and 11 patients had moderate to severe alopecia. The granulocyte nadir was above 1000 μl in 83% of evaluable courses, 500-1000 μl in 6%, and less than 500 μl in 11% of courses. Two patients developed neutropenia-associated fever. A platelet nadir below 100,000/μl was seen after only 8% of courses, and only 1 patient had platelets below 50,000/μl. In conclusion, epirubicin has modest activity in hepatocellular carcinoma and is well tolerated when given by hepatic arterial infusion.

UR - http://www.scopus.com/inward/record.url?scp=0025666378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025666378&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 197

EP - 201

JO - Regional Cancer Treatment

JF - Regional Cancer Treatment

SN - 0935-0411

IS - 4

ER -